Fundamental Analysis of X4 PHARMACEUTICALS INC(NASDAQ:XFOR) stock

Fundamental Rating

Overall XFOR gets a fundamental rating of 1 out of 10. We evaluated XFOR against 568 industry peers in the Biotechnology industry. XFOR has a bad profitability rating. Also its financial health evaluation is rather negative. XFOR is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

XFOR had negative earnings in the past year.

XFOR had a negative operating cash flow in the past year.

XFOR had negative earnings in each of the past 5 years.

XFOR had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

With an excellent Return On Assets value of -9.41%, XFOR belongs to the best of the industry, outperforming 87.96% of the companies in the same industry.

XFOR has a better Return On Equity (-28.11%) than 80.00% of its industry peers.

		Industry Rank	Sector Rank
ROA	-9.41%
ROE	-28.11%
ROIC	N/A

ROA(3y)-72.75%

ROA(5y)-60.4%

ROE(3y)-162.49%

ROE(5y)-122.83%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for XFOR so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

Compared to 1 year ago, XFOR has more shares outstanding

XFOR has more shares outstanding than it did 5 years ago.

XFOR has a worse debt/assets ratio than last year.

2.2 Solvency

XFOR has an Altman-Z score of -4.83. This is a bad value and indicates that XFOR is not financially healthy and even has some risk of bankruptcy.

XFOR has a worse Altman-Z score (-4.83) than 61.42% of its industry peers.

A Debt/Equity ratio of 1.26 is on the high side and indicates that XFOR has dependencies on debt financing.

With a Debt to Equity ratio value of 1.26, XFOR is not doing good in the industry: 79.47% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
Debt/Equity	1.26
Debt/FCF	N/A
Altman-Z	-4.83

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

XFOR has a Current Ratio of 4.89. This indicates that XFOR is financially healthy and has no problem in meeting its short term obligations.

With a Current ratio value of 4.89, XFOR perfoms like the industry average, outperforming 53.45% of the companies in the same industry.

A Quick Ratio of 4.80 indicates that XFOR has no problem at all paying its short term obligations.

Looking at the Quick ratio, with a value of 4.80, XFOR is in line with its industry, outperforming 54.34% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	4.89
Quick Ratio	4.8

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 22.78% over the past year.

EPS 1Y (TTM)22.78%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-1700%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, XFOR will show a quite strong growth in Earnings Per Share. The EPS will grow by 16.94% on average per year.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y60.17%

EPS Next 2Y5.06%

EPS Next 3Y13.12%

EPS Next 5Y16.94%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for XFOR. In the last year negative earnings were reported.

Also next year XFOR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as XFOR's earnings are expected to grow with 13.12% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y5.06%

EPS Next 3Y13.12%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

XFOR does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

X4 PHARMACEUTICALS INC

NASDAQ:XFOR (12/17/2024, 8:31:15 PM)

After market: 0.7499 +0.01 (+1.52%)

0.7387

+0.09 (+14.53%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap125.99M

Analysts

Price Target

Short Float %

Short Ratio

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-9.41%
ROE	-28.11%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.01

Health

		Industry Rank	Sector Rank
Debt/Equity	1.26
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	4.89
Quick Ratio	4.8
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)22.78%

EPS 3YN/A

EPS 5Y

EPS Q2Q%

EPS Next Y60.17%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

X4 PHARMACEUTICALS INC (XFOR)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens